Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)
China
· Delayed Price · Currency is CNY 52.03
-0.99 (-1.87%)
At close: Apr 3, 2025, 2:57 PM CST
SHA:688192 Revenue
In the year 2024, Dizal (Jiangsu) Pharmaceutical had annual revenue of 360.39M CNY with 294.79% growth. Dizal (Jiangsu) Pharmaceutical had revenue of 21.94M in the quarter ending December 31, 2024, a decrease of -57.13%.
Revenue
360.39M
Revenue Growth
+294.79%
P/S Ratio
59.75
Revenue / Employee
620.30K
Employees
581
Market Cap
21.73B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Medicine | 27.98B |
| Shenzhen Mindray Bio-Medical Electronics | 37.11B |
| WuXi AppTec | 37.92B |
| Aier Eye Hospital Group | 20.62B |
| Zhangzhou Pientzehuang Pharmaceutical., | 10.91B |
| Shanghai United Imaging Healthcare | 10.30B |
| Yunnan Baiyao Group Co.,Ltd | 40.03B |
| Sichuan Biokin Pharmaceutical | 5.82B |